A5006187231- Chronic Obstructive Pulmonary Disease (COPD) Research
- Asthma and respiratory diseases
- Respiratory Support and Mechanisms
- Pediatric health and respiratory diseases
- Long-Term Effects of COVID-19
- Inhalation and Respiratory Drug Delivery
- Injury Epidemiology and Prevention
- Pulmonary Hypertension Research and Treatments
- COVID-19 and healthcare impacts
- Childhood Cancer Survivors' Quality of Life
- Cardiovascular Function and Risk Factors
- Frailty in Older Adults
- School Health and Nursing Education
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Body Composition Measurement Techniques
- Congenital Heart Disease Studies
- Nutrition and Health in Aging
- Respiratory and Cough-Related Research
University Hospitals of Leicester NHS Trust
2025
University of Leicester
2023-2025
NIHR Leicester Biomedical Research Centre
2023-2024
National Institute for Health Research
2023
Admission to hospital with an acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is associated a high risk morbidity and mortality. Biologic treatment reduces COPD exacerbations in patients eosinophilic inflammation. Mepolizumab, monoclonal antibody interleukin 5, inflammation, but its effects on future hospitalization mortality are uncertain. In this phase 2b, double-blind, placebo-controlled trial, we randomly assigned hospitalized AECOPD blood eosinophil count greater...
<b>Background:</b> Fatigue and muscle weakness are commonly reported following COVID-19 supporting a need to explore possible mechanisms. <b>Aims objectives:</b> To assess the role of quality index (MQI) in ongoing symptoms recovery from hospitalisation with COVID-19. <b>Methods:</b> Hospitalised survivors for across 35 UK sites were prospectively recruited (PHOSP-COVID study.) MQI was assessed using ratio maximum hand grip strength total body lean mass either DXA or BIA 5 months after...
The impact of seasonality on the morbidity due to acute exacerbations chronic obstructive pulmonary disease (AECOPD) is well recognised, with winter months typically associated increased respiratory infections and healthcare utilisation among COPD population [1]. first wave COVID pandemic saw at least 50% decline in AECOPD admissions fewer viral triggers [2]. However, after relaxation lockdown measures, it unknown if there has been a longer-term shift seasonal pattern hospitalisations their...
<b>Background:</b> Previous reports have described obesity as a major risk factor for non-recovery following hospitalisation COVID-19. <b>Aims and objectives:</b> To assess body composition differences between individuals who either recovered or not with <b>Methods:</b> Adults hospitalised COVID-19 across 35 UK sites were recruited. Body was assessed using BIA DXA 5 months after discharge. Whole lean fat mass values combined from both modalities regional measures are reported. Self-reported...
<b>Background:</b> During the COVID-19 pandemic, hospitalizations for acute exacerbation of COPD(AECOPD)were reduced, particularly due to viral triggers. However, with easing lockdown and facemask use, future pattern hospitalised exacerbations is unclear. <b>Objective:</b> To assess seasonal variation AECOPD rate various triggers during year(2022) Methodology We conducted an observational cohort study admissions in Leicester, UK. Subjects were prospectively recruited at admission categorised...